Page last updated: 2024-12-05

ethylene dimethacrylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ethylene dimethacrylate (EDMA) is a cross-linking monomer widely used in the preparation of various polymeric materials. Its synthesis involves the reaction of ethylene glycol with methacrylic acid in the presence of a catalyst. EDMA is known for its ability to enhance the mechanical strength, rigidity, and thermal stability of polymers. It is extensively studied for its potential applications in various fields, including dentistry, biomedical engineering, and coatings. The cross-linking nature of EDMA contributes to its effectiveness in forming strong and durable networks within polymers. Its biocompatibility and non-toxicity make it suitable for use in dental composites and other biomedical devices. Furthermore, EDMA is used in the production of coatings that exhibit excellent adhesion, abrasion resistance, and chemical stability. The research on EDMA focuses on optimizing its properties, exploring novel applications, and understanding its interactions with other monomers and polymers.'

ethylene glycol dimethacrylate : The enoate ester that is the 1,2-bis(methacryloyl) derivative of ethylene glycol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7355
CHEMBL ID1709582
CHEBI ID53378
CHEBI ID53436
SCHEMBL ID15636
MeSH IDM0046128

Synonyms (87)

Synonym
AKOS015837657
2-propenoic acid, 2-methyl-, 1,2-ethanediyl ester
ethylene methacrylate
ethanediol dimethacrylate
nsc24166
sr 206
97-90-5
methacrylic acid, ethylene ester
nsc-24166
glycol dimethacrylate
ethylenedimethyacrylate
ethylene glycol dimethacrylate
sartomer sr 206
ethylene glycol bis(methacrylate)
1,2-bis(methacryloyloxy)ethane
diglycol dimethacrylate
ethylene dimethacrylate
ethane-1,2-diyl bis(2-methylacrylate)
einecs 202-617-2
ccris 179
ethyldiol metacrylate
1,2-ethanediyl 2-methyl-2-propenoate
hsdb 5313
nsc 24166
brn 1776663
ethyldiol methacrylate
ageflex egdm
methacrylic acid ethylene ester
NCGC00163970-02
ethylene glycol dimethacrylate, 98%, contains 90-110 ppm monomethyl ether hydroquinone as inhibitor
NCGC00163970-01
2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate
E0102
25852-47-5
peg-dma
1,2-ethanediol dimethacrylate
CHEBI:53378
egdma
2-methyl-2-propenoic acid 1,2-ethanediyl ester
CHEBI:53436 ,
25721-76-0
2-(methacryloyloxy)ethyl 2-methylacrylate
A845762
NCGC00163970-03
cas-97-90-5
dtxsid1026615 ,
NCGC00257144-01
tox21_303153
dtxcid106615
tox21_201914
NCGC00259463-01
FT-0688078
ethyleneglycol dimethacrylate
unii-7bk5g69305
ec 202-617-2
2-propenoic acid, 2-methyl-, 1,1'-(1,2-ethanediyl) ester
7bk5g69305 ,
glycol dimethacrylate [inci]
ethylene methacrylate [hsdb]
EPITOPE ID:131323
2-(dimethylamino)ethyl (2,5-dioxo-4,4-diphenyl-imidazolidin-1-yl)methyl carbonate; methanesulfonic acid
SCHEMBL15636
perkalink 401
nk ester 1g
ageflex egdma
tgm 1
mfm-416
2-(methacryloyloxy)ethyl 2-methylacrylate #
1,2-bis(methacryloyoxy) ethane
W-100100
CHEMBL1709582
ethylene glycol dimethacrylate,99%(egdma)
mfcd00008590
ethylene glycol dimethacrylate, (stabilized with hq)
ethylene glycol dimethacrylate (stabilized with hq)
2-[(2-methylprop-2-enoyl)oxy]ethyl 2-methylprop-2-enoate
CS-W015656
12738-39-5
2-propenoic acid,2-methyl-,1,1'-(1,2-ethanediyl)ester
Q2231462
benzenepropanoic acid, 2,5-dimethoxy-.alpha.-oxo-
D70270
porapak t (80-100 mesh astm) for gc
1,2-bis-(methacryloyloxy)-ethane
AS-78075
F71209
1,2-ethanediol dimethacrylate ethylene dimethacrylate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" To study adverse effects on the skin in dentists possibly caused by acrylic resin-based materials."( On composite resin materials. Degradation, erosion and possible adverse effects in dentists.
Ortengren, U, 2000
)
0.31
" To study the adverse effects on skin in dentists, a questionnaire was sent to 3500 randomly selected Swedish dentists."( On composite resin materials. Degradation, erosion and possible adverse effects in dentists.
Ortengren, U, 2000
)
0.31

Bioavailability

ExcerptReferenceRelevance
" Nanotechnology is one of the most dynamically developing disciplines and is a powerful tool to increase the bioavailability of drugs."( [Synthesis of nanoparticles for dental drug delivery systems].
Bakó, J; Borbély, J; Hegedûs, C; Márton, I; Szepesi, M, 2007
)
0.34
"Ophthalmic drug delivery through eye drops is inefficient because of low corneal bioavailability and short residence time in tears."( Temperature sensitive contact lenses for triggered ophthalmic drug delivery.
Chauhan, A; Jung, HJ, 2012
)
0.38
" In vivo pharmacokinetic study displayed the relative bioavailability of the gastro-floating MWCNT@LC-MIP was 578."( Floating liquid crystalline molecularly imprinted polymer coated carbon nanotubes for levofloxacin delivery.
Huang, YP; Liu, ZS; Tan, XX; Zhang, LP, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" These polymers represent a potential valid system for drug delivery and this study indicates that the selective binding characteristic of molecularly imprinted polymers is promising for the preparation of novel controlled release drug dosage form."( Molecularly imprinted polymers for 5-fluorouracil release in biological fluids.
Alhaiqu, F; Cirillo, G; Iemma, F; Matricardi, P; Picci, N; Puoci, F, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
cross-linking reagentA reagent with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between macromolecules, principally side chains of amino acids in proteins, allowing the locations of naturally reactive areas within the proteins to be identified.
polymerisation monomerAny compound used as a monomer for a polymerisation process. The term is generally used in relation to industrial polymerisation processes.
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
enoate esterAn alpha,beta-unsaturated carboxylic ester of general formula R(1)R(2)C=CR(3)-C(=O)OR(4) (R(4) =/= H) in which the ester C=O function is conjugated to a C=C double bond at the alpha,beta position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency19.33120.006038.004119,952.5996AID1159521
AR proteinHomo sapiens (human)Potency3.51730.000221.22318,912.5098AID588515; AID743042
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency24.93170.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency34.66540.000817.505159.3239AID1159527
farnesoid X nuclear receptorHomo sapiens (human)Potency0.43640.375827.485161.6524AID743220
estrogen nuclear receptor alphaHomo sapiens (human)Potency63.17150.000229.305416,493.5996AID743069
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency48.96620.001024.504861.6448AID743215
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency7.76060.023723.228263.5986AID743222
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency63.171519.739145.978464.9432AID1159509
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency76.95880.000323.4451159.6830AID743066
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency22.38720.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (602)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (1.83)18.7374
1990's48 (7.97)18.2507
2000's181 (30.07)29.6817
2010's324 (53.82)24.3611
2020's38 (6.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.14 (24.57)
Research Supply Index6.45 (2.92)
Research Growth Index5.34 (4.65)
Search Engine Demand Index90.78 (26.88)
Search Engine Supply Index2.16 (0.95)

This Compound (52.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.32%)5.53%
Reviews5 (0.80%)6.00%
Case Studies11 (1.75%)4.05%
Observational0 (0.00%)0.25%
Other610 (97.13%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]